Provided by Tiger Fintech (Singapore) Pte. Ltd.

NANOBIOTIX SPON ADS EACH REP 1 ORD SHS

3.25
+0.17505.70%
Volume:388.00
Turnover:1.27K
Market Cap:153.83M
PE:-3.88
High:3.35
Open:3.35
Low:3.25
Close:3.07
Loading ...

Company Profile

Company Name:
NANOBIOTIX SPON ADS EACH REP 1 ORD SHS
Exchange:
NASDAQ
Establishment Date:
2003
Employees:
110
Office Location:
60 rue de Wattignies,Paris,Ile-de-France,France
Zip Code:
75012
Fax:
33 1 40 26 04 44
Introduction:
Nanobiotix S.A., a clinical-stage biotechnology, focuses on developing product candidates for the treatment of cancer and other unmet medical needs. Its lead product candidate is NBTXR3, a sterile aqueous suspension of crystalline hafnium oxide nanoparticles used for the treatment of soft tissue sarcoma, head and neck cancers, liver cancers, prostate cancer, pancreatic cancer, esophageal cancer, rectal cancer, and non-small cell lung cancer. Nanobiotix S.A. has a partnership with Lian Oncology Limited to develop and commercialize NBTXR3 in Greater China, South Korea, Singapore, and Thailand. Nanobiotix S.A. was incorporated in 2003 and is headquartered in Paris, France.

Directors

Name
Position
Alain Herrera
Member of Supervisory Board
Anne Marie Graffin
Vice Chairwoman
Christophe Douat
Observer
Enno Spillner
Member of Supervisory Board
Gary Phillips
chairman

Shareholders

Name
Position
Anne Juliette Hermant
Chief People Officer
Bart Van Rhijn
chief financial officer and member of the executive board
Laurent Levy
co-founder and chief executive officer